Advertisement

Topics

Novo Nordisk leans on Victoza as competition increases

06:12 EDT 9 Aug 2017 | BioPharmaDive

After struggling with the pricing environment in the U.S., the Danish drugmaker is seeing strength return to its diabetes business. 

Original Article: Novo Nordisk leans on Victoza as competition increases

NEXT ARTICLE

More From BioPortfolio on "Novo Nordisk leans on Victoza as competition increases"

Quick Search
Advertisement